Novartis Set to Achieve 100% Renewable Electricity in Its European Operations

Novartis has announced the signature of five virtual power purchase agreements (VPPAs), which are expected to collectively add more than 275 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve 100% renewable electricity in its European operations through VPPAs. 

“At Novartis, environmental sustainability is aligned with our purpose to reimagine medicine to improve and extend people’s lives,” said Montse Montaner, Chief Sustainability Officer at Novartis. “Energy efficiency and renewable energy solutions are the cornerstones of our strategy for reducing emissions. These agreements mark a major milestone on the Novartis environmental sustainability journey to be carbon neutral across its operations by 2025 and across its value chain by 2030.”

Under the agreements, wind and solar electricity will be generated from six renewable energy projects being developed by three different providers – Acciona, EDP Renewables and Enel Green Power. All projects will be located in Spain. The projects are expected to be online by 2023 and aim to address the company’s carbon footprint across its European operations over a period of 10 years from the start of operations. This is equivalent to removing approximately 113 000 passenger vehicles from the road each year1. These European agreements follow the VPPA recently implemented with the Santa Rita East windfarm in Texas, US, which currently addresses 100% of the electricity used in our operations in the US and Canada.

“Novartis has demonstrated tremendous and ongoing sustainability leadership in the pharmaceutical industry,” said John Powers, Vice President of Global Renewables and Cleantech at Schneider Electric. “Executing five deals allows Novartis to diversify risk across technology, location, counterparty and deal structure making for a balanced portfolio of Spanish renewable energy.  We want to congratulate Novartis on this sustainability milestone and shaping a clean energy future.” 

Schneider Electric, a global specialist in energy management, acted as advisor in the project. Global law firm Baker McKenzie advised Novartis on all legal aspects relating to the VPPAs.

Environmental sustainability at Novartis

At Novartis, we aim to drive sustainability through our own operations, as well as those of our suppliers, and we have set ambitious targets to minimize our impacts on climate, waste and water. We are committed to using resources efficiently and reducing greenhouse gas (GHG) emissions, which affect the climate. Our ambition is to make the company both energy and climate resilient. We aim to become carbon neutral in our own operations (Scope 1 and 2) by 2025, and to achieve carbon neutrality across our supply chain (Scope 1, 2 and 3) by 2030. As a stepping stone to achieve our ambition, we have an approved Science Based Target which commits us to a 35% reduction in absolute emissions across our value chain without using carbon offsets.

For more information:

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.